Clinical and genetic aspects of menopausal hormone therapy - a modern paradigm. What changed COVID-19 pandemic?
- Authors: Zhuravleva I.S.1, Khamoshina M.B.1, Orazov M.R.1, Dmitrieva E.M.1, Azova M.M.1
-
Affiliations:
- Peoples’ Friendship University of Russia
- Issue: Vol 26, No 4 (2022): GINECOLOGY
- Pages: 364-372
- Section: GINECOLOGY
- URL: https://journals.rudn.ru/medicine/article/view/32990
- DOI: https://doi.org/10.22363/2313-0245-2022-26-4-364-372
Cite item
Full Text
Abstract
In the modern paradigm of public health protection, much attention is paid to the health of women in peri- and postmenopause, and a personalized approach prevails. It is generally recognized that the pathogenetic therapy of menopausal disorders is hormone therapy. But the COVID-19 pandemic has made its own adjustments to the routine strategy of choosing menopausal hormone therapy (MHT). The purpose of this review was to analyze studies on the dependence of the effectiveness of MHT on clinical and genetic aspects in the context of the ongoing COVID-19 pandemic. The review highlights the main risks of MHT for thromboembolic diseases and coagulation complications characteristic of COVID-19, discusses genetic predispositions that aggravate the course of the post-COVID period, as well as the effectiveness of estrogens in protecting the vascular endothelium and increasing the number of CD4+ T cells, providing an adequate immune response when infected with SARS-CoV-2. Numerous studies show that the complications characteristic of the severe course of COVID-19 are multifactorial in nature and cannot be unambiguously explained only by genetic predisposition. However, with the development of personalized medicine, special attention should be paid to the study of genetic aspects that can equally contribute to the occurrence of menopausal disorders in healthy women and aggravate the course of the post-pregnancy period. The data presented allow us to conclude that in the context of the ongoing COVID-19 pandemic at the population level, MHT can bring significant benefits to women during menopause due to the beneficial effect of estrogens on vascular walls. Additional study of the relationship between the course of the postcovid period in MHT users and polymorphisms of candidate genes that determine the risks of thrombotic complications and metabolic consequences is required.
Keywords
About the authors
Irina S. Zhuravleva
Peoples’ Friendship University of Russia
Author for correspondence.
Email: izhuravas@mail.ru
ORCID iD: 0000-0001-9425-8616
Moscow, Russian Federation
Marina B. Khamoshina
Peoples’ Friendship University of Russia
Email: izhuravas@mail.ru
ORCID iD: 0000-0003-1940-4534
Moscow, Russian Federation
Mekan R. Orazov
Peoples’ Friendship University of Russia
Email: izhuravas@mail.ru
ORCID iD: 0000-0002-5342-8129
Moscow, Russian Federation
Elena M. Dmitrieva
Peoples’ Friendship University of Russia
Email: izhuravas@mail.ru
ORCID iD: 0000-0002-3973-8833
Moscow, Russian Federation
Madina M. Azova
Peoples’ Friendship University of Russia
Email: izhuravas@mail.ru
ORCID iD: 0000-0002-7290-1196
Moscow, Russian Federation
References
- Schoenaker DAJM, Jackson СА, Rowlands JV, Mishra GD. Socioeconomic position, lifestyle factors and age at natural menopause: a systematic review and meta-analyses of studies across six continents. Int. J. Epidemiol. 2014;43(5):1542-1562. doi: 10.1093/ije/dyu094
- Lumsden MA. The NICE Guideline - M enopause: diagnosis and management. Climacteric. 2016;19(5):426-429. doi: 10.1080/13697137.2016.1222483
- Ortmann O, Beckermann MJ, Inwald EC, Strowitzki T, Windler E, Tempfer C. Peri- and postmenopause-diagnosis and interventions interdisciplinary S 3 guideline of the association of the scientific medical societies in Germany (AWMF 015/062): short version. Arch Gynecol Obstet. 2020;302(3):763-777. doi: 10.1007/s00404-020-05682-4
- Khamoshina MB, Zhuravleva IS, Artemenko YS, Dmitrieva EM. Hormone-dependent diseases of the female reproductive system in the era of COVID-19: quo vadis? Obstetrics and Gynecology: news, opinions, training. 2021;9(3):35-42. https://doi.org/10.33029/23039698-2021-9-3suppI-35-42 (In Russian).
- Ulumbekova GE, Khudova IY. Assessment of demographic, social and economic effect when taking menopausal hormone therapy. Orgzdrav: news, opinions, training. Vestnik VSHOUZ. 2020;6(4):23- 53. https://doi.org/10.24411 / 2411-8621-2020-14002 (In Russian).
- Schulman S. Coronavirus Disease 2019, Prothrombotic Factors, and Venous. Thromboembolism. Semin Thromb Hemost. 2020;46(7):772-776. doi: 10.1055/s-0040-1710337
- Makatsariya AD, Slukhanchuk EV, Bitsadze VO, Khizroeva JK, Tretyakova MV, Tsibizova VI, Shkoda AS, Grandone E, Elalamy I, Rizzo G, Gris J-С, Schulman S, Brenner B. COVID-19, Hemostasis Disorders and Risk of Thrombotic Complications. Annals of the Russian Academy of Medical Sciences. 2020;75(4):306-317. doi: 10.15690/ vramn1368. (In Russian).
- Khamoshina M.B., Zhuravleva I.S., Dmitrieva E.M., Lebedeva M.G. Menopausal hormone therapy and postcovid syndrome: new realities. Medical Herald of the South of Russia. 2022;13(2):26-33. doi: 10.21886/2219-8075-2022-13-2-26-33 (In Russian).
- Seeland U, Coluzzi F, Simmaco M, Mura C, Bourne PE, Heiland M, Preissner R, Preissner S. Evidence for treatment with estradiol for women with SARS-CoV-2 infection. BMC Med. 2020;18(1):369. doi: 10.1186/s12916-020-01851-z
- Lapić I, Radić Antolic M, Horvat I, Premužić V, Palić J, Rogić D, Zadro R. Association of polymorphisms in genes encoding prothrombotic and cardiovascular risk factors with disease severity in COVID-19 patients: A pilot study. J Med Virol. 2022;94(8):3669-3675. doi: 10.1002/jmv.27774
- Gorodin VN, Moisova DL, Zotov SV, Vanyukov AA, Podsadnaya AA, Tikhonenko YV. The role of polymorphism of hemostasis genes in the pathogenesis of COVID-19. Infectious diseases. 2021;19(2):16-26. doi: 10.20953/1729-9225-2021-2-16-26 (In Russian).
- Subbotovskaya AI, Tsvetovskaya GA, Slepukhina AA, Lifshits GI. Polymorphism of the plasminogen activator inhibitor gene in assessing the risk of thrombosis of various localization (pilot study). Russ J Cardiol. 2015;10(126):50-53. https://doi.org/10.15829/15604071-2015-10-50-53 (In Russian).
- Burlacu A, Genovesi S, Popa IV, Crisan-Dabija R. Unpuzzling COVID-19 Prothrombotic State: Are Preexisting Thrombophilic Risk Profiles Responsible for Heterogenous Thrombotic Events? Clin Appl Thromb Hemost. 2020;26:1076029620952884. doi: 10.1177/1076029620952884
- Yalım Z, Tutgun Onrat S, Alan S, Aldemir M, Avşar A, Doğan İ, Onrat E. The effects of genetic polymorphisms and diabetes mellitus on the development of peripheral artery disease. Turk Kardiyol Dern Ars. 2020;48(5):484-493. doi: 10.5543/tkda.2020.15686
- Ponti G, Pastorino L, Manfredini M, Ozben T, Oliva G, Kaleci S, Iannella R, Tomasi A. COVID-19 spreading across world correlates with C 677T allele of the methylenetetrahydrofolate reductase (MTHFR) gene prevalence. J Clin Lab Anal. 2021;35(7): e23798. doi: 10.1002/jcla.23798
- Raghubeer S, Matsha TE. Methylenetetrahydrofolate (MTHFR), the One-Carbon Cycle, and Cardiovascular Risks. Nutrients. 2021;13(12):4562. doi: 10.3390/nu13124562
- Bouzidi N, Hassine M, Fodha H, Ben Messaoud M, Maatouk F, Gamra H, Ferchichi S. Association of the methylene-tetrahydrofolate reductase gene rs1801133 C 677T variant with serum homocysteine levels, and the severity of coronary artery disease. Sci. Rep. 2020;10:10064. doi: 10.1038/s41598-020-66937-3
- Fan Y, Wu L, Zhuang W. Methylenetetrahydrofolate Reductase Gene rs1801133 and rs1801131 Polymorphisms and Essential Hypertension Risk: A Comprehensive Analysis. Cardiovasc Ther. 2022;2022:2144443. doi: 10.1155/2022/2144443
- Liew SC, Gupta ED. Methylenetetrahydrofolate reductase (MTHFR) C 677T polymorphism: epidemiology, metabolism and the associated diseases. Eur J Med Genet. 2015;58(1):1-10. doi: 10.1016/j. ejmg.2014.10.004
- Liu YT, Lin CC, Wang L, Nfor ON, Hsu SY, Lung CC, Tantoh DM, Chang HR, Liaw YP. Peripheral Vascular Disease Susceptibility Based on Diabetes Mellitus and rs17367504 Polymorphism of the MTHFR Gene. Diabetes Metab Syndr Obes. 2021;14:2381-2388. doi: 10.2147/DMSO.S 309242
- Lu ML, Ku WC, Syifa N, Hu SC, Chou CT, Wu YH, Kuo PH, Chen CH, Chen WJ, Wu TH. Developing a Sensitive Platform to Measure 5-Methyltetrahydrofolate in Subjects with MTHFR and PON 1 Gene Polymorphisms. Nutrients. 2022;14(16):3320. doi: 10.3390/ nu14163320
- Ma L, Li J, Yuan Y, Chen W, Zhao J. Effect of methylenetetrahydrofolate reductase C 677T polymorphism on serum folate but not vitamin B 12 levels in patients with H-type hypertension. Mol Biol Rep. 2022;49(10):9535-9541. doi: 10.1007/s11033-022- 07844-w
- Kong Y, Han J, Wu X, Zeng H, Liu J, Zhang H. VEGF-D: a novel biomarker for detection of COVID-19 progression. Crit Care. 2020;24(1):373. doi: 10.1186/s13054-020-03079-y
- Remuzgo-Martínez S, Genre F, Pulito-Cueto V, Atienza-Mateo B, Mora Cuesta VM, Iturbe Fernández D, Fernández Rozas SM, Lera-Gómez L, Alonso Lecue P, Ussetti MP, Laporta R, Berastegui C, Solé A, Pérez V, De Pablo Gafas A, Gualillo O, Cifrián JM, LópezMejías R, González-Gay MÁ. Role of VEGF Polymorphisms in the Susceptibility and Severity of Interstitial Lung Disease. Biomedicines. 2021;9(5):458. doi: 10.3390/biomedicines9050458
- Shimizu Y, Arima K, Noguchi Y, Yamanashi H, Kawashiri SY, Nobusue K, Nonaka F, Aoyagi K, Nagata Y, Maeda T. Vascular endothelial growth factor (VEGF) polymorphism rs3025039 and atherosclerosis among older with hypertension. Sci Rep. 2022;12(1):5564. doi: 10.1038/s41598-022-09486-1
- Palmer BR, Paterson MA, Frampton CM, Pilbrow AP, Skelton L, Pemberton CJ, Doughty RN, Ellis CJ, Troughton RW, Richards AM, Cameron VA. Vascular endothelial growth factor-A promoter polymorphisms, circulating VEGF-A and survival in acute coronary syndromes. PLoS One. 2021;16(7): e0254206. doi: 10.1371/journal. pone.0254206
- Zhao X, Meng L, Jiang J, Wu X. Vascular endothelial growth factor gene polymorphisms and coronary heart disease: a systematic review and meta-analysis. Growth Factors. 2018;36(3-4):153-163. doi: 10.1080/08977194.2018.1477141
- Yin XX, Zheng XR, Peng W, Wu ML, Mao XY. Vascular Endothelial Growth Factor (VEGF) as a Vital Target for Brain Inflammation during the COVID-19 Outbreak. ACS Chem Neurosci. 2020;11(12):1704-1705. doi: 10.1021/acschemneuro.0c00294.
- Camarda N, Travers R, Yang VK, London C, Jaffe IZ. VEGF Receptor Inhibitor-Induced Hypertension: Emerging Mechanisms and Clinical Implications. Curr Oncol Rep. 2022;24(4):463-474. doi: 10.1007/s11912-022-01224-0
- Gnagnarella P, Raimondi S, Aristarco V, Johansson H, Bellerba F, Corso F, De Angelis SP, Belloni P, Caini S, Gandini S. Ethnicity as modifier of risk for Vitamin D receptors polymorphisms: Comprehensive meta-analysis of all cancer sites. Crit Rev Oncol Hematol. 2021;158:103202. doi: 10.1016/j.critrevonc.2020.103202.
- Gnagnarella P, Raimondi S, Aristarco V, Johansson HA, Bellerba F, Corso F, Gandini S. Vitamin D Receptor Polymorphisms and Cancer. Adv Exp Med Biol. 2020;1268:53-114. doi: 10.1007/978-3-030-46227-7_4
- Georgakopoulou A, Papadimitriou-Olivgeris M, Karakantza M, Marangos M. Role of inherited thrombophilic profile on survival of patients with sepsis. J Investig Med. 2019;67(8):1131-1135. doi: 10.1136/jim-2019-001034
- Fu L, Ma J, Yan S, Si Q. A meta-analysis of VDR polymorphisms and postmenopausal osteoporosis. Endocr Connect. 2020;9(9):882-889. doi: 10.1530/EC-20-0296
- Rivera-Paredez B, Quezada-Sánchez AD, Denova-Gutiérrez E, Torres-Ibarra L, Flores YN, Salmerón J, Velázquez-Cruz R. Diet Modulates the Effects of Genetic Variants on the Vitamin D Metabolic Pathway and Bone Mineral Density in Mexican Postmenopausal Women. J Nutr. 2021;151(7):1726-1735. doi: 10.1093/jn/nxab067
- Liao JL, Qin Q, Zhou YS, Ma RP, Zhou HC, Gu MR, Feng YP, Wang BY, Yang L. Vitamin D receptor Bsm I polymorphism and osteoporosis risk in postmenopausal women: a meta-analysis from 42 studies. Genes Nutr. 2020;15(1):20. doi: 10.1186/s12263-020-00679-9.
- Marozik P, Rudenka A, Kobets K, Rudenka E. Vitamin D Status, Bone Mineral Density, and VDR Gene Polymorphism in a Cohort of Belarusian Postmenopausal Women. Nutrients. 2021;13(3):837. doi: 10.3390/nu13030837
- Wang S, Ai Z, Song M, Yan P, Li J, Wang S. The association between vitamin D receptor FokI gene polymorphism and osteoporosis in postmenopausal women: a meta-analysis. Climacteric. 2021;24(1):74-79. doi: 10.1080/13697137.2020.1775806
- Deuster E, Jeschke U, Ye Y, Mahner S, Czogalla B. Vitamin D and VDR in Gynecological Cancers-A Systematic Review. Int J Mol Sci. 2017;18(11):2328. doi: 10.3390/ijms18112328
- Zeidan NMS, Lateef HMAE, Selim DM, Razek SA, AbdElrehim GAB, Nashat M, ElGyar N, Waked NM, Soliman AA, Elhewala AA, Shehab MMM, Ibraheem AAA, Shehata H, Yousif YM, Akeel NE, Hashem MIA, Ahmed AA, Emam AA, Abdelmohsen MM, Ahmed MF, Saleh ASE, Eltrawy HH, Shahin GH, Nabil RM, Hosny TA, Abdelhamed MR, Afify MR, Alharbi MT, Nagshabandi MK, Tarabulsi MK, Osman SF, Abd-Elrazek ASM, Rashad MM, El-Gaaly SAA, Gad SAB, Mohamed MY, Abdelkhalek K, Yousef AA. Vitamin D deficiency and vitamin D receptor FokI polymorphism as risk factors for COVID-19. Pediatr Res. 2022:1-8. doi: 10.1038/s41390-022-02275-6
- Zenciroglu A, Okumus N. Association of vitamin D receptor gene FokI and TaqI polymorphisms and risk of RDS. J Matern Fetal Neonatal Med. 2020 Nov;33(21):3640-3646. doi: 10.1080/147670 58.2019.1582629
- Ruiz-Ballesteros AI, Meza-Meza MR, Vizmanos-Lamotte B, Parra-Rojas I, de la Cruz-Mosso U. Association of Vitamin D Metabolism Gene Polymorphisms with Autoimmunity: Evidence in Population Genetic Studies. Int J Mol Sci. 2020 Dec 17;21(24):9626. doi: 10.3390/ijms21249626
- Dobrijevic Z, Robajac D, Gligorijevic N, Šunderic M, Penezic A, Miljuš G, Nedic O. The association of ACE 1, ACE 2, TMPRSS 2, IFITM3 and VDR polymorphisms with COVID-19 severity: A systematic review and meta-analysis. EXCLI J. 2022;21:818-839. doi: 10.17179/excli2022-4976
- Fernandez Lahore G, Raposo B, Lagerquist M, Ohlsson C, Sabatier P, Xu B, Aoun M, James J, Cai X, Zubarev RA, Nandakumar KS, Holmdahl R. Vitamin D 3 receptor polymorphisms regulate T cells and T cell-dependent inflammatory diseases. Proc Natl Acad Sci USA. 2020;117(40):24986-24997. doi: 10.1073/pnas.2001966117
- Scazzone C, Agnello L, Bivona G, Lo Sasso B, Ciaccio M. Vitamin D and Genetic Susceptibility to Multiple Sclerosis. Biochem Genet. 2021;59(1):1-30. doi: 10.1007/s10528-020-10010-1
- Yang X, Ru J, Li Z, Jiang X, Fan C. Lower vitamin D levels and VDR FokI variants are associated with susceptibility to sepsis: a hospital-based case-control study. Biomarkers. 2022;27(2):188-195. doi: 10.1080/1354750X.2021.2024598
- Memon MA, Baig S, Siddiqui PQR. Fok1 VDR Gene Polymorphisms as the Risk factor for Diabetes Mellitus. J Coll Physicians Surg Pak. 2022 May;32(5):581-585. doi: 10.29271/jcpsp.2022.05.581
- Sattar NA, Shaheen S, Hussain F, Jamil A. Association analysis of vitamin D receptor gene polymorphisms in North England population with Type 2 diabetes mellitus. Afr Health Sci. 2021;21(1):8-14. doi: 10.4314/ahs.v21i1.3
- Totonchi H, Rezaei R, Noori S, Azarpira N, Mokarram P, Imani D. Vitamin D Receptor Gene Polymorphisms and the Risk of Metabolic Syndrome (MetS): A Meta-Analysis. Endocr Metab Immune Disord Drug Targets. 2021;21(5):943-955. doi: 10.2174/18715303 20666200805101302
- Yao Liu, Shen HW, Ye XH, He XF. Evaluation of association studies and a systematic review and meta-analysis of VDR polymorphisms in type 2 diabetes mellitus risk. Medicine (Baltimore). 2021 Jul 16;100(28): e25934. doi: 10.1097/MD.0000000000025934
- Yu S, Li X, Yu F, Mao Z, Wang Y, Xue Y, Sun H, Ba Y, Wang C, Li W. New evidence for associations between vitamin D receptor polymorphism and obesity: case-control and family-based studies. J Hum Genet. 2020;65(3):281-285. doi: 10.1038/s10038-019-0702-5.
- Faghfouri AH, Faghfuri E, Maleki V, Payahoo L, Balmoral A, Khaje Bishak Y. A comprehensive insight into the potential roles of VDR gene polymorphism in obesity: a systematic review. Arch Physiol Biochem. Arch Physiol Biochem. 2022;128(6):1645-1657. doi: 10.1080/13813455.2020.1788097
- Fronczek M, Strzelczyk JK, Osadnik T, Biernacki K, Ostrowska Z. VDR Gene Polymorphisms in Healthy Individuals with Family History of Premature Coronary Artery Disease. Dis Markers. 2021;2021:8832478. doi: 10.1155/2021/8832478
- González Rojo P, Pérez Ramírez C, Gálvez Navas JM, Pineda Lancheros LE, Rojo Tolosa S, Ramírez Tortosa MDC, Jiménez Morales A. Vitamin D-Related Single Nucleotide Polymorphisms as Risk Biomarker of Cardiovascular Disease. Int J Mol Sci. 2022;23(15):8686. doi: 10.3390/ijms23158686
- Santos BR, Casanova G, Silva TR, Marchesan LB, Oppermann K, Spritzer PM. Are vitamin D deficiency and VDR gene polymorphisms associated with high blood pressure as defined by the ACC/AHA 2017 criteria in postmenopausal women? Maturitas. 2021;149:26-33. doi: 10.1016/j.maturitas.2021.05.004
- Abdollahzadeh R, Shushizadeh MH, Barazandehrokh M, Choopani S, Azarnezhad A, Paknahad S, Pirhoushiaran M, Makani SZ, Yeganeh RZ, Al-Kateb A, Heidarzadehpilehrood R. Associati on of Vitamin D receptor gene polymorphisms and clinical/severe outcomes of COVID-19 patients. Infect Genet Evol. 2021;96:105098. doi: 10.1016/j.meegid.2021.105098
- Apaydin T, Polat H, Dincer Yazan C, Ilgin C, Elbasan O, Dashdamirova S, Bayram F, Tukenmez Tigen E, Unlu O, Tekin AF, Arslan E, Yilmaz I, Haklar G, Ata P, Gozu H. Effects of vitamin D receptor gene polymorphisms on the prognosis of COVID-19. Clin Endocrinol (Oxf). 2022 Jun;96(6):819-830. doi: 10.1111/cen.14664
- Interim guidelines for the prevention, diagnosis and treatment of novel coronavirus infection (COVID-19). Version 16 (08/18/2022). Ministry of Health of the Russian Federation 2022. 239 p. (In Russian).
- Greenhalgh T, Sivan M, Delaney B, Evans R, Milne R. Long covid-an update for primary care. BMJ. 2022.22;378:e072117. doi: 10.1136/bmj-2022-072117